View by Year:
Select Year View All 2016 2015 2014 2013 2012
Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas.
Oncotarget, Aug-12-2016;[Epub ahead of print].
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Oncogene, Apr-7-2016;35(14):1797-810. Epub 2015 Jun 29.
Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.
Journal of cancer research and clinical oncology, May-2015;141(5):901-8. Epub 2014 Nov 4.
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.
PloS one, 2015;[epublish]10(7):e0132134.
NEMO is essential for Kaposi's sarcoma-associated herpesvirus-encoded vFLIP K13-induced gene expression and protection against death receptor-induced cell death, and its N-terminal 251 residues are sufficient for this process.
Journal of virology, Jun-2014;88(11):6345-54. Epub 2014 Mar 26.
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
Oncogene, May-29-2014;33(22):2928-37. Epub 2013 Jun 24.
Kaposi's sarcoma-associated herpesvirus oncoprotein K13 protects against B cell receptor-induced growth arrest and apoptosis through NF-κB activation.
Journal of virology, Feb-2013;87(4):2242-52. Epub 2012 Dec 12.
Kaposi's sarcoma associated herpesvirus encoded viral FLICE inhibitory protein K13 activates NF-κB pathway independent of TRAF6, TAK1 and LUBAC.
PloS one, 2012;7(5):e36601.